Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma
The purpose of this study is to determine the response rate to the combination of doxorubicin and valproate acid in patients with MM failing after at least one previous chemotherapy regimen including platinum derivatives .
Malignant Mesothelioma
DRUG: Valproate plus doxorubicin
Response rate, Every 3 courses
Survival, Survival will be dated from the day of registration until death or last follow up|Toxicity, After each course of chemotherapy and at the end of treatment
The purpose of this study is to determine the response rate to the combination of doxorubicin and valproate acid in patients with MM failing after at least one previous chemotherapy regimen including platinum derivatives .